The effect of 10% pegagan (centella asiatica (L.) urban) extract cream on melanin amount in the guinea pig skin vitiligo model
DOI:
https://doi.org/10.66344/jpad.v33i3.2251Keywords:
Centella extract, Melanin, HydroquinoneAbstract
Background Pegagan is one of the plants used by the community for medicinal purposes; it contains a variety of compounds, including the following: Pegagan contains antioxidant and anti-inflammatory effects. The in vivo effects of repigmenting chemicals generated from centella asiatica extract have not been explored prior to this study.
Objective To demonstrate that 10% pegagan extract cream affects melanin levels in guinea pig models of vitiligo.
Methods This is a strictly experimental study with a post-test-only control group design involving the administration of 10% centella asiatica extract cream. In this study, 16 male guinea pigs were divided into two groups. Both groups of guinea pigs had cream containing hydroquinone administered to their backs daily for eight days. The control group then did not get any treatment. The treatment group received a 10% Pegagan extract lotion for fourteen days. Histopathological examination of tissue stained with Masson-Fontaine. The amount of melanin is based on the ratio of pixels in the melanin area to the total number of pixels in the epidermal tissue.
Results The group that got 10% Pegagan extract cream had the highest concentration of melanin, and the difference was statistically significant (p0.05).
Conclusion The conclusion of this study is that 10% centella asiatica extract cream improves the level of melanin in the skin of guinea pigs with a vitiligo model.
References
1. Ezzedin K and Harris JE. Vitiligo. In: Kang S, Amagai M, Bruckner AL, Enk 35 AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatrick Dermatology. Ed 9th. New York: McGraw Hill. 2019:1330-50
2. Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-12.
3. Rizal Y, Lestari S. Insidensi vitiligo di poliklinik kulit dan kelamin RSUP Dr. M Djamil Padang tahun 2001-2006. MDVI. 2008;35(1):77.
4. Sandoval M. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011;10(12):762-5.
5. Sravani PV. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol Dermatol. 2009;75:268-71.
6. 12Olasade OA. Dermatology Psychosocial problems in patients with vitiligo in Nigeria. Sudan J Dermatol. 2007;5:51-8.
7. Kruger C, Schallreuter KU. Cumulative life course impairment in vitiligo. Curr Probl Dermatol. 2013;44:102–17.
8. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148:373-4.
9. Suman B, Pranjal D, Rakesh M. Assessment of Quality of Life in Vitiligo patients attending a tertiary care hospital – a cross sectional study. Ind Psychiatry J. 2021;30(1):62-66.
10. Asri E, Kampar P. Hubungan Vitiligo Area Scoring Index (VASI) dengan Dermatology Life Question Index (DLQI) pada pasien vitiligo di RSUP.Dr.M.Djamil Padang Periode 2015-2016. Jurnal Kesehatan Andalas. 2019;8(3):1-5.
11. Nurina DR, Rahmadewi R. Studi Retrospektif: Profil pasien baru vitiligo. Period Dermatol Venereol. 2022;28(2):130-6.
12. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the published work. J Dermatol. 2011;38:419-31.
13. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. Vitiligo Working Group. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017;77(1):17–29.
14. Whitton M, Pinart M, Batchelor J.M, Leonardi J, Gonzalez U, Jiyad Z. Evidance based management of vitiligo:summary of a cochrane systematic review. Br J Dermatol. 2016;174(5):962-69.
15. Zhu Y, Wang S, Xu A. A mouse model of vitiligo induced by monobenzone. Exp. Dermatol. 2021;7:499-501.
16. Yaobin P, Shi w, Yingjie H, Qing N, Jing L, Yejing Y, et al. Plant-derived compounds as promising Therapeutics for vitiligo. Frontiers in Pharmacology. Front Pharmacol. 2021;12:685116.
17. Riding L,RichardM, Harris J. Mouse Model for Human Vitiligo. Curr Protoc Immunol. 2019;124(1):e63.
18. Reddy J, Ranganathan, Jeldi H. A study of phytochemical analysis and antioxidant potentials of use in the treatment of vitiligo. European Journal of Biomedical and pharmaceutical sciences. 2014;1:471-9.
19. Zhu Y, Zhong L, Peng J, Yuan Q, Xu A. The therapeutic effect baicalin on vitiligo mice. Biol Pharma Bull. 2019;42(9):1450-5
20. Huo S.X, Wang Q. The Effect of Butin on the Vitiligo Mouse Model Induced by Hydroquinone. Phytother Res. 2017;31(5): 740–6.
21. Kowichi J, Hiroko, Madhu A, Pathak, Thomas B. Fitzpatrick. Mechanism of depigmentation by Hydroquinone. J Invest Dermatol.1974;62(4):436-49.
22. Sun B, Lili W, You W, Chengfei, Lingling Q, Misa H et al. Therapeutic Potential of Centella asiatoca and its Triterpenes: A Review. Front Pharmacol. 2020;11: 568032.
23. Committee on Herbal Medicinal Product. Asessment report on centella asiatica (L.) Urban, herba. 44 European Medicines Agency. 2010.p:1-44.
24. Lee, T. H., Seo, J. O., Baek, S. H., Kim, S. Y. Inhibitory effects of resveratrol on melanin synthesis in ultraviolet B-induced pigmentation in guinea pig skin. Biomol Therapeut, 2014;22(1):35–40.
25. Oyenihi P, Chegu NN, Oguntibeju, Masola B. Centella asiatica enhances hepatic antioxidant status and regulates hepatic inflammatory cytokines in type 2 diabetic rats. Pharm Biol. 2017:55(1):1671-8.
26. Marasri J, Sunisa S. Development of herbal juice from centella asiatica: antioxidant property and nutritional. Food science and technology. 2022.Vol. 42.
DOI: 10.1590/fst.93722
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Marina Harahap
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
